A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas
A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas
复制标题
DOI：
10.1158/1078-0432.ccr-09-0035
复制
发表时间：
2009-07-01
影响因子：
11.5
通讯作者：
Begent, Richard H.
中科院分区：
文献类型：
--
作者：
Meyer, Tim;Gaya, Andrew M.;Begent, Richard H.
目的：在临床前模型中，I-131-A5 B7抗癌胚抗原（CEA）抗体（I-131-A5 B7）与血管破坏剂考布他汀-A4-磷酸盐（CA 4P）联合使用的放射免疫治疗产生了与单独使用任何一种药物不同的治愈效果。我们进行了一项I期试验，确定了胃肠道腺癌患者中这种联合治疗的剂量限制性毒性（DLT）、最大耐受剂量、疗效和机制。
Purpose: In preclinical models, radioimmunotherapy with I-131-A5B7 anti-carcinoembryonic antigen (CEA) antibody (I-131-A5B7) combined with the vascular disruptive agent combretastatin-A4-phosphate (CA4P) produced cures unlike either agent alone. We conducted a phase I trial determining the dose-limiting toxicity (DLT), maximum tolerated dose, efficacy, and mechanism of this combination in patients with gastrointestinal adenocarcinomas.Experimental Design: Patients had CEA of 10 to 1,000 mu g/L, QTc